Impaired cliff avoidance reaction in dopamine transporter knockout mice

Psychopharmacology

Volumn 227, Issue 4, 2013, Pages 741-749

  Yamashita, Motoyasu ^a   Sakakibara, Yasufumi ^a   Hall, F Scott ^b   Numachi, Yohtaro ^a   Yoshida, Sumiko ^a   Kobayashi, Hideaki ^a   Uchiumi, Osamu ^a   Uhl, George R ^b   Kasahara, Yoshiyuki ^a   Sora, Ichiro ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Attention deficit hyperactivity disorder; Behavioral inhibition; Cliff avoidance reaction; Dopamine transporter knockout mice; Impulsivity; Prepulse inhibition of acoustic startle response

Indexed keywords

DOPAMINE TRANSPORTER; METHYLPHENIDATE; NISOXETINE; NORADRENALIN TRANSPORTER;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; ATTENTION DEFICIT DISORDER; AVOIDANCE BEHAVIOR; CLIFF AVOIDANCE REACTION; CONTROLLED STUDY; DRUG MECHANISM; EXPERIMENTAL MOUSE; IMPULSIVENESS; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SENSORY GATING; STEREOTYPY;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FLUOXETINE; IMPULSIVE BEHAVIOR; MALE; METHYLPHENIDATE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; SENSORY GATING; STARTLE REACTION;

EID: 84878704262     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3009-9     Document Type: Article

References (44)

1. Arime Y, Kubo Y, Sora I (2011) Animal models of attention-deficit/ hyperactivity disorder. Biol Pharm Bull 34(9):1373-1376. doi: 10.1248/bpb.34.1373
2. Arime Y, Kasahara Y, Hall FS, Uhl GR, Sora I (2012) Cortico-subcortical neuromodulation involved in the amelioration of prepulse inhibition deficits in dopamine transporter knockout mice. Neuropsychopharmacology 37(11):2522-2530. doi: 10.1038/npp.2012.114
3. Arnsten AF, Pliszka SR (2011) Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav 99(2):211-216. doi: 10.1016/j.pbb.2011.01.020
4. Aron AR, Dowson JH, Sahakian BJ, Robbins TW (2003) Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 54(12):1465-1468. doi: 10.1016/S0006-3223(03)00609-7
5. Barkley RA (1997) Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 121(1):65-94. doi: 10.1037/0033-2909.121.1.65
6. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelly AE, Schmeichel B, Hamilton C, Spencer RC (2006) Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 60(10):1111-1120. doi: 10.1016/j.biopsych.2006.04.022
7. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27(5):699-711. doi: 10.1016/S0893-133X(02)00346-9
8. Creese I, Iversen SD (1973) Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Res 55(2):369-382. doi: 10.1016/0006-8993(73)90302-8
9. Cyr M, Beaulieu JM, Laakso A, Sotnikova TD, Bohn LM, Gainetdinov RR, Caron MG (2003) Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A 100(19):11035-11040. doi: 10.1073/pnas.1831768100
10. Dalley JW, Mar AC, Economidou D, Robbins TW (2008) Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry. Phamacol Biochem Behav 90(2):250-260. doi: 10.1016/j.pbb.2007. 12.021
11. DeVito EE, Balckwell AD, Clark L, Kent L, Dezsery AM, Turner DC, Aitken MR, Sahakian BJ (2009) Methylphenidate improves response inhibition but not reflection-impulsivity in children with attention deficit hyperactivity disorder (ADHD). Psychopharmacol (Berl) 202(1-3):531-539. doi: 10.1007/s00213-008-1337-y
12. Eagle DM, Baunez C (2010) Is there an inhibitory-response-control system in the rat? Evidence from anatomical and pharmacological studies of behavioral inhibition. Neurosci Biobehav Rev 34(1):50-72. doi: 10.1016/j.neubiorev.2009.07. 003
13. Engert V, Pruessner JC (2008) Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate. Curr Neuropharmacol 6(4):322-328. doi: 10.2174/157015908787386069
14. Fernagut PO, Chalon S, Diguet E, Guilloteau D, Tison F, Jaber M (2003) Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience 116(4):1123-1130. doi: 10.1016/S0306-4522(02)00778-9
15. Gainetdinov RR, Westel WC, Jones SR, Levin ED, Jaber M, Caron MG (1999) Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 285(5400):397-401. doi: 10.1126/science.283.5400.397
16. Goddard AW, Ball SG, Martinez J, Robinson MJ, Yang CR, Russell JM, Shekhar A (2010) Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress Anxiety 27(4):339-350. doi: 10.1002/da.20642
17. Haenisch B, Bonisch H (2011) Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther 129(3):352-368. doi: 10.1016/j.pharmthera.2010.12.002
18. Hernandez LF, Segovia G, Mora F (2008) Chronic treatment with a dopamine uptake blocker changes dopamine and acetylcholine but not glutamate and GABA concentrations in prefrontal cortex, striatum and nucleus accumbens of the awake rat. Neurochem Int 52(3):457-469. doi: 10.1016/j.neuint.2007.08.005
19. Hiramatsu M, Cho AK, Nabeshima T (1989) Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol 166(3):359-366. doi: 10.1016/0014-2999(89)90346-4
20. Humby T, Wilkinson LS (2011) Assaying dissociable elements of behavioural inhibition and impulsivity: translational utility of animal models. Curr Opin Pharmacol 11(5):534-539. doi: 10.1016/j.coph.2011.06.006
21. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci U S A 95(7):4029-4034
22. Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T (2010) Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem 114(1):259-270. doi: 10.1111/j.1471-4159.2010.06750.x
23. Kumakura K, Nomura H, Toyoda T, Hashikawa K, Noguchi T, Takeda K, Ichijo H, Tsunoda M, Funatsu T, Ikegami D, Narita M, Suzuki T, Matsuki N (2010) Hyperactivity in novel environment with increased dopamine and impaired novelty preference in apoptosis signal-regulating kinase 1 (ASK1)-deficient mice. Neurosci Res 66(3):313-320. doi: 10.1016/j.neures.2009.12.003
24. Kuroda K, Yamada S, Tanaka M, Iizuka M, Yano H, Mori D, Tsuboi D, Nishioka T, Namba T, Iizuka Y, Kubota S, Nagai T, Ibi D, Wang R, Enomoto A, Isotani-Sakakibara M, Asai N, Kimura K, Kiyonari H, Abe T, Mizoguchi A, Sokabe M, Takahashi M, Yamada K, Kaibuchi K (2011) Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse. Hum Mol Genet 20(23):4666-4683. doi: 10.1093/hmg/ddr400
25. Matsuoka Y, Furuyashiki T, Yamada K, Nagai T, Bito H, Tanaka Y, Kitaoka S, Ushikubi F, Nabeshima T, Narumiya S (2005) Prostaglandin E receptor EP1 controls impulsive behavior under stress. Proc Natl Acad Sci U S A 102(44):16066-16071. doi: 10.1073/pnas.0504908102
26. Nigg JT (2000) On inhibition/disinhibition in developmental psychopathology: views from cognitive and personality psychology and a working inhibition taxonomy. Psychol Bull 126(2):220-246. doi: 10.1037/0033-2909.126.2. 220
27. Pattij T, Vanderschuren LJ (2008) The neuropharmacology of impulsive behaviour. Trends Pharmacol Sci 29(4):192-199. doi: 10.1016/j.tips.2008.01.002
28. Pogorelov VM, Rodriguiz RM, Insco ML, Caron MG, Westel WC (2005) Novelty seeking and stereotypic activation of behavior in mice with disruption of the Dat1 gene. Neuropsychopharmacology 30(10):1818-1831. doi: 10.1038/sj.npp.1300724
29. Powell SB, Zhou X, Geyer MA (2009) Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res 204(2):282-294. doi: 10.1016/j.bbr.2009.04.021
30. Ralph RJ, Paulus MP, Fumagalli F, Caron MG, Geyer MA (2001) Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J Neurosci 21(1):305-313
31. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI (1998) Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex echibit sparse immunoreactivity for the dopamine transporter. J Neurosci 18(7):2697-2708
32. Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto T, Lesch KP, Murphy DL, Hall FS, Uhl GR, Sora I (2004) Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29(10):1790-1799. doi: 10.1038/sj.npp.1300476
33. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, Lesch KP, Murphy DL, Uhl GR (1998) Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mouse. Proc Natl Acad Sci U S A 95(13):7699-7704
34. Spielewoy C, Roubert C, Hamon M, Nosten-Bertrand M, Betancur C, Giros B (2000) Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav Pharmacol 11(3-4):279-290
35. Tripp G, Wickens JR (2009) Neurobiology of ADHD. Neuropharmacology 57(7-8):579-589. doi: 10.1016/j.neuropharm.2009.07.026
36. Uchiumi O, Kasahara Y, Fukui A, Hall FS, Uhl GR, Sora I (2013) Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine. Neuropharmacology 64:348-356. doi: 10.1016/j.neuropharm.2012.07.016
37. van der Kooij MA, Glennon JC (2007) Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. Neurosci Biobehav Rev 31(4):597-618. doi: 10.1016/j.neubiorev.2006.12.002
38. Wehmeier PM, Schacht A, Wolff C, Otto WR, Dittmann RW, Banaschewski T (2011) Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tracking device. J Child Adolesc Psychopharmacol 21(5):433-444. doi: 10.1089/cap.2010.0142
39. Winstanley CA (2011) The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders. Br J Pharmacol 164(4):1301-1321. doi: 10.1111/j.1476-5381.2011.01323.x
40. Xu TX, Sotnikova TD, Liang C, Zhang J, Jung JU, Spealman RD, Gainetdinov RR, Yao WD (2009) Hyperdopaminergic tone erodes prefrontal long-term potential via a D2 receptor-operated protein phosphatase gate. J Neurosci 29(45):14086-14099. doi: 10.1523/JNEUROSCI.0974-09.2009
41. Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101(1):57-66. doi: 10.1016/S0092-8674(00)80623-6
42. Yamashita M, Fukushima S, Shen HW, Hall FS, Uhl GR, Numachi Y, Kobayashi H, Sora I (2006) Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 31(10):2132-2139. doi: 10.1038/sj.npp.1301009
43. Yoshida S, Numachi Y, Matsuoka H, Sato M (1998) Impairment of cliff avoidance reaction induced by subchronic methamphetamine administration and restraint stress: comparison between two inbred strains of rats. Prog Neuropsychopharmacol Biol Psychiatry 22(6):1023-1032. doi: 10.1016/S0278- 5846(98)00050-5
44. Young JW, van Enkhuizen J, Winstanley CA, Geyer MA (2011) Increased risk-taking behavior in dopamine transporter knockdown mice: future support for a mouse model of mania. J Psychopharmacol 25(7):934-943. doi: 10.1177/0269881111400646